BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT02045966
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
- Conditions
- Stage IV or Recurrent Non-Small Cell Lung Cancer
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 541
- Registration Number
- NCT02041533
- Locations
- 🇯🇵
Local Institution - 0159, Akashi, Hyogo, Japan
🇺🇸Southern Cancer Center, Inc., Mobile, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 121
- Registration Number
- NCT02038933
- Locations
- 🇬🇧
Local Institution, Sutton, Surrey, United Kingdom
🇫🇷Hopital Saint Eloi, Montpellier Cedex 05, France
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 116
- Registration Number
- NCT02038946
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇬🇧Local Institution, Sutton, Surrey, United Kingdom
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 153
- Registration Number
- NCT02037737
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT02034565
- Locations
- 🇺🇸
Mds Pharma Services, Neptune, New Jersey, United States
Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT02034591
- Locations
- 🇺🇸
Healthcare Discoveries, LLC D/B/A Icon Development Solutions, San Antonio, Texas, United States
Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT02034578
- Locations
- 🇺🇸
Parexel Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 238
- Registration Number
- NCT02032888
- Locations
- 🇺🇸
University Gastroenterology, Providence, Rhode Island, United States
🇺🇸Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸Tarrant County Inf Dis Assoc, Fort Worth, Texas, United States
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 173
- Registration Number
- NCT02032901
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸University of Florida Hepatology Research, Gainesville, Florida, United States
🇺🇸Midland Florida Clinical Research Center, LLC, Deland, Florida, United States